Genetic determinants of risk in pulmonary arterial hypertension : international genome-wide association studies and meta-analysis

Rhodes, Christopher J and Batai, Ken and Bleda, Marta and Haimel, Matthias and Southgate, Laura and Germain, Marine and Pauciulo, Michael W and Hadinnapola, Charaka and Aman, Jurjan and Girerd, Barbara and Arora, Amit and Knight, Jo and Hanscombe, Ken B and Karnes, Jason H and Kaakinen, Marika and Gall, Henning and Ulrich, Anna and Harbaum, Lars and Cebola, Inês and Ferrer, Jorge and Lutz, Katie and Swietlik, Emilia M and Ahmad, Ferhaan and Amouyel, Philippe and Archer, Stephen L and Argula, Rahul and Austin, Eric D and Badesch, David and Bakshi, Sahil and Barnett, Christopher and Benza, Raymond and Bhatt, Nitin and Bogaard, Harm J and Burger, Charles D and Chakinala, Murali and Church, Colin and Coghlan, John G and Condliffe, Robin and Corris, Paul A and Danesino, Cesare and Debette, Stéphanie and Elliott, C Gregory and Elwing, Jean and Eyries, Melanie and Fortin, Terry and Franke, Andre and Frantz, Robert P and Frost, Adaani and Garcia, Joe G N and Ghio, Stefano (2019) Genetic determinants of risk in pulmonary arterial hypertension : international genome-wide association studies and meta-analysis. Lancet Respiratory Medicine, 7 (3). pp. 227-238. ISSN 2213-2600

Abstract

BACKGROUND: Rare genetic variants cause pulmonary arterial hypertension, but the contribution of common genetic variation to disease risk and natural history is poorly characterised. We tested for genome-wide association for pulmonary arterial hypertension in large international cohorts and assessed the contribution of associated regions to outcomes. METHODS: We did two separate genome-wide association studies (GWAS) and a meta-analysis of pulmonary arterial hypertension. These GWAS used data from four international case-control studies across 11 744 individuals with European ancestry (including 2085 patients). One GWAS used genotypes from 5895 whole-genome sequences and the other GWAS used genotyping array data from an additional 5849 individuals. Cross-validation of loci reaching genome-wide significance was sought by meta-analysis. Conditional analysis corrected for the most significant variants at each locus was used to resolve signals for multiple associations. We functionally annotated associated variants and tested associations with duration of survival. All-cause mortality was the primary endpoint in survival analyses. FINDINGS: A locus near SOX17 (rs10103692, odds ratio 1·80 [95% CI 1·55-2·08], p=5·13 × 10 -15) and a second locus in HLA-DPA1 and HLA-DPB1 (collectively referred to as HLA-DPA1/DPB1 here; rs2856830, 1·56 [1·42-1·71], p=7·65 × 10 -20) within the class II MHC region were associated with pulmonary arterial hypertension. The SOX17 locus had two independent signals associated with pulmonary arterial hypertension (rs13266183, 1·36 [1·25-1·48], p=1·69 × 10 -12; and rs10103692). Functional and epigenomic data indicate that the risk variants near SOX17 alter gene regulation via an enhancer active in endothelial cells. Pulmonary arterial hypertension risk variants determined haplotype-specific enhancer activity, and CRISPR-mediated inhibition of the enhancer reduced SOX17 expression. The HLA-DPA1/DPB1 rs2856830 genotype was strongly associated with survival. Median survival from diagnosis in patients with pulmonary arterial hypertension with the C/C homozygous genotype was double (13·50 years [95% CI 12·07 to >13·50]) that of those with the T/T genotype (6·97 years [6·02-8·05]), despite similar baseline disease severity. INTERPRETATION: This is the first study to report that common genetic variation at loci in an enhancer near SOX17 and in HLA-DPA1/DPB1 is associated with pulmonary arterial hypertension. Impairment of SOX17 function might be more common in pulmonary arterial hypertension than suggested by rare mutations in SOX17. Further studies are needed to confirm the association between HLA typing or rs2856830 genotyping and survival, and to determine whether HLA typing or rs2856830 genotyping improves risk stratification in clinical practice or trials. FUNDING: UK NIHR, BHF, UK MRC, Dinosaur Trust, NIH/NHLBI, ERS, EMBO, Wellcome Trust, EU, AHA, ACClinPharm, Netherlands CVRI, Dutch Heart Foundation, Dutch Federation of UMC, Netherlands OHRD and RNAS, German DFG, German BMBF, APH Paris, INSERM, Université Paris-Sud, and French ANR.